Search results for "Lymphocyte"

showing 10 items of 2280 documents

Follow Up On CD8-Depleted Donor-Lymphocyte Infusions After T-Cell Depleted Allogeneic Hemopoietic Stem Cell Transplantation

2013

We applied prophylactic CD8-depleted (CD8depl) donor lymphocyte infusions (DLI) in the setting of T-cell depleted reduced-intensity allogeneic hematopoietic stem cell transplantation (HSCT) in a phase I/II trial. T-cell depletion was carried out by the use of high-dose Alemtuzumab (100 mg or 60 mg for unrelated or sibling donor transplantation, respectively). We have demonstrated the feasibility of this approach after having treated 23 patients in this protocol (Meyer et al. Blood 2007). From 2004 to 2011, 134 patients with different hematologic diseases were included and followed for a median observation time of 1.5 years after transplantation (range, 1.5-9 years). Median age was 56 years …

medicine.medical_specialtybusiness.industryLymphocytemedicine.medical_treatmentImmunologyCell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseaseBiochemistryGastroenterologylaw.inventionSurgeryTransplantationmedicine.anatomical_structureGraft-versus-host diseaseRandomized controlled triallawInternal medicineCohortmedicineAlemtuzumabbusinessCD8medicine.drugBlood
researchProduct

Treg activation status depends on psoriasis therapy regime

2020

medicine.medical_specialtybusiness.industryPsoriasismedicineMEDLINEHumansPsoriasisTh17 CellsDermatologymedicine.diseasebusinessT-Lymphocytes RegulatoryDermatologyJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Longitudinal investigation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in older patients in the province of Palermo (So…

2020

IntroductionClinical presentation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in old adults from Southern Italy is little known. This study aims to investigate the mortality risk related to risk factors, therapy and clinical course and to suggest prognostic indicators based on day-to-day follow-up of clinical and laboratory findings.Material and methodsIt was designed as a retrospective longitudinal cohort study of adult SARS-CoV-2 patients admitted at Partinico COVID Hospital in Palermo, Southern Italy. Patients were recruited between 4 March and 25 April and followed up until 31 May 2020, day-to-day until death or hospital discharge. Clinical data, laboratory…

medicine.medical_specialtybusiness.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)General Medicinechronic kidney failuremedicine.diseaseSettore MED/01 - Statistica MedicaChronic kidney failureOlder patientsdiabeteInternal medicineDiabetes mellitusD-dimerPandemicMedicineDementiaNeutrophils/Lymphocytes Ratiobusinessprognostic factordementiaArchives of medical science : AMS
researchProduct

Significance of Neutrophil to Lymphocyte Ratio (NLR) and Platelet Lymphocyte Ratio (PLR) in Diabetic Foot Ulcer and Potential New Therapeutic Targets

2021

Diabetic foot ulcer (DFU) is a well-known complication of diabetes and a significant burden on the national health systems. The neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio are inexpensive and easily accessible biomarkers that have proved to be useful in several inflammatory, infectious and cardiovascular diseases. We carried out a comprehensive review examining the association of NLR and PLR with the onset and progression of DFU. PLR and NLR were significantly increased in patients with DFU, compared with a control group of T2DM patients without DFU, and correlate well with DFU severity, evaluated by Wagner and IWGDF grading scales. In patients with diabetic foot infect…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentOsteomyelitisGeneral MedicineSystemic inflammationmedicine.diseaseGastroenterologyDiabetic foot ulcerAmputationDiabetes mellitusInternal medicinediabetes diabetic foot ulcer inflammation neutrophil-to-lymphocyte ratio (NLR) platelet lymphocyte ratio (PLR)medicineSurgeryClinical significancemedicine.symptomNeutrophil to lymphocyte ratioComplicationbusiness
researchProduct

Impact of Sars-CoV2 Infection on 491 Hematological Patients: The Ecovidehe Multicenter Study

2020

INTRODUCTION Coronavirus disease 2019 (COVID-19) caused by SARS-CoV2 virus is thought to be more severe in patients with prior hematological diseases. There is evidence suggesting that hematological patients are particularly vulnerable and have a higher risk of developing severe events, with higher mortality rate than general population. However, the available data are limited, and prognostic factors at admission still remain unclear. With this background, our aims were to analyze the impact of hematological diseases and their therapy on the COVID-19 severity and to identify clinical and biological risk factors to predict the outcome in these patients. METHODS We carried out a multicenter …

medicine.medical_specialtyeducation.field_of_studybusiness.industryMortality rateImmunologyPopulation203.Lymphocytes Lymphocyte Activation and Immunodeficiency including HIV and Other InfectionsRetrospective cohort studyCell BiologyHematologyDiseasemedicine.diseaseBiochemistryComorbidityMulticenter studyInternal medicineIntensive caremedicineIn patienteducationbusinessBlood
researchProduct

P120: The value of neutrophil and lymphocyte count in frail older women

2014

medicine.medical_specialtymedicine.anatomical_structurebusiness.industryInternal medicineLymphocyteMedicineGeriatrics and GerontologybusinessGerontologyValue (mathematics)European Geriatric Medicine
researchProduct

P2516Low relative lymphocyte count as a marker of frailty in patients with acute coronary syndromes

2017

medicine.medical_specialtymedicine.anatomical_structurebusiness.industryLymphocyteInternal medicinemedicineIn patientCardiology and Cardiovascular MedicinebusinessEuropean Heart Journal
researchProduct

Induction of dendritic cell maturation and modulation of dendritic cell-induced immune responses by prostaglandins

2000

Dendritic cells (DC) are the most potent antigen-presenting cells of the immune system. In this study we investigated the effects of various prostaglandins (PG) on the stimulatory capacity of DC. DC were generated from peripheral progenitor cells in the presence of IL-4 and GM-CSF and stimulated with IL-1, IL-6 and TNF-alpha on day 7. Simultaneously, PG (PGD(2), PGE(1), PGE(2), PGF(2 alpha), PGI(2)) were added at various concentrations (10(-5) to 10(-9) M) on day 7. In all experiments, PGE(2) had the most potent influence on the maturation of the DC, followed by other PG in the order PGE(1) > PGD(2) > PGF(2 alpha) > PGI(2). In addition, the expression of the surface molecules CD40, CD54, CD…

medicine.medical_specialtymedicine.medical_treatmentDermatologyLymphocyte ActivationProinflammatory cytokinechemistry.chemical_compoundInterferon-gammaAntigens CDInternal medicinemedicineHumansCells CulturedMHC class IIForskolinCD40biologyDose-Response Relationship DrugInterleukin-6Prostaglandin D2Tumor Necrosis Factor-alphaColforsinCell DifferentiationGeneral MedicineDendritic cellDendritic CellsMolecular biologyInterleukin-12Coculture TechniquesEndocrinologyCytokinechemistryBucladesinebiology.proteinProstaglandinsCytokinesInterleukin-2lipids (amino acids peptides and proteins)CD80CD8Interleukin-1
researchProduct

Modulation of IL-2, IFN-γ, TNF-α and IL-4 production in mice of different ages by thymopentin

1992

The effect of an immunomodulator drug thymopentin (TP5) on the production of various cytokines (IFN-gamma, IL-2, IL-4, TNF-alpha) in mice of different ages has been studied. TP5 enhanced IL-2, TNF-alpha and IFN-gamma production but reduced the IL-4 secretion by splenocytes from aged mice (greater than 120 week old) in vitro. However, it had no effect on the IL-2, IFN-gamma, TNF-alpha or IL-4 production by splenocytes from young and adult mice. TP5 injected subcutaneously was able to induce high levels of IL-2 production by splenocytes from all groups of mice. The TP5 effect on TNF-alpha and IFN-gamma was similar, even though it was significant only in old mice. Furthermore, TP5 was able to …

medicine.medical_specialtymedicine.medical_treatmentImmunologyMitogen stimulationInterferon-gammaMiceT-Lymphocyte SubsetsInternal medicinemedicineSplenocyteAnimalsThymopentinSecretionLymphocytesInterleukin 4PharmacologyMice Inbred BALB CTumor Necrosis Factor-alphabusiness.industryAge FactorsIn vitroCytokineEndocrinologyInterleukin-2FemaleInterleukin-4Thymopentinbusinessmedicine.drugInternational Journal of Immunopharmacology
researchProduct

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

2015

The immunogenicity of malignant cells has recently been acknowledged as a critical determinant of efficacy in cancer therapy. Thus, besides developing direct immunostimulatory regimens, including dendritic cell-based vaccines, checkpoint-blocking therapies, and adoptive T-cell transfer, researchers have started to focus on the overall immunobiology of neoplastic cells. It is now clear that cancer cells can succumb to some anticancer therapies by undergoing a peculiar form of cell death that is characterized by an increased immunogenic potential, owing to the emission of the so-called "damage-associated molecular patterns" (DAMPs). The emission of DAMPs and other immunostimulatory factors by…

medicine.medical_treatmentAPOPTOTIC CALRETICULIN EXPOSUREanti-tumor immunityimmunogenicityPHOTODYNAMIC THERAPY0302 clinical medicinetranslational medicineoncoimmunologyImmunology and AllergyCytotoxic T cellMedicineAnti-tumor immunity; Immunogenicity; Immunotherapy; Molecular medicine; Oncoimmunology; Patient prognosis; Translational medicine; Immunology; Immunology and Allergy0303 health sciencesanti-tumor immunity; immunogenicity; immunotherapy; molecular medicine; oncoimmunology; patient prognosis; translational medicineRIBOSOMAL-PROTEIN DIMERClassificationddc:3. Good health030220 oncology & carcinogenesisImmunogenic cell deathMolecular MedicineimmunotherapyACTIVATING POLYPEPTIDE-IIHIGH HYDROSTATIC-PRESSURElcsh:Immunologic diseases. AllergyANTICANCER IMMUNE-RESPONSESImmunology3122 Cancers610 Medicine & healthpatient prognosis03 medical and health sciencesImmune systemHUMAN TUMOR-CELLSFORMYL PEPTIDE RECEPTORS030304 developmental biologybusiness.industryTranslational medicineBiology and Life SciencesCYTOTOXIC T-LYMPHOCYTESImmunotherapyDendritic cellMolecular medicineNEGATIVE BREAST-CANCERImmunologyCancer cellmolecular dicine3111 Biomedicinebusinesslcsh:RC581-607Frontiers in Immunology
researchProduct